Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Castle Biosciences Inc (CSTL)
Price$32.70Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M | $22.8M |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M | $53.0M | $44.6M | $17.5M |
| Gross margin | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% | 84.54% | 85.91% | 76.75% |
| Research & development | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M | $13.3M | $7.4M | $4.9M |
| Operating expenses | $316.0M | $263.2M | $242.8M | $177.9M | $118.3M | $59.5M | $37.2M | $21.3M |
| Operating income | −$42.8M | $8.7M | −$68.0M | −$72.9M | −$40.1M | −$6.5M | $7.3M | −$3.8M |
| Operating margin | −12.44% | 2.61% | −30.93% | −53.16% | −42.60% | −10.44% | 14.13% | −16.83% |
| EBITDA | −$2.0M | $24.7M | −$55.6M | −$62.3M | −$36.7M | −$6.1M | $7.7M | −$3.5M |
| EBITDA margin | −0.59% | 7.43% | −25.32% | −45.47% | −38.98% | −9.69% | 14.82% | −15.42% |
| Net income | −$24.2M | $18.2M | −$57.5M | −$67.1M | −$31.3M | −$10.3M | $5.3M | −$6.4M |
| Net profit margin | −7.02% | 5.49% | −26.15% | −48.99% | −33.26% | −16.42% | 10.17% | −27.94% |
| Basic EPSper basic share | -$0.83 | $0.66 | -$2.14 | -$2.58 | -$1.24 | -$0.54 | $0.35 | -$5.33 |
| Diluted EPSper diluted share | -$0.83 | $0.62 | -$2.14 | -$2.58 | -$1.24 | -$0.54 | -$0.21 | -$5.33 |
Owners
Reported shareholders
10.79%of listed shares
BlackRock, Inc.3.29M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.79%3.29M shares |
RTW INVESTMENTS, LP | 9.11%2.78M shares |
PRINCIPAL FINANCIAL GROUP INC | 5.66%1.73M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.02%1.23M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.01%918.67K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.76%840.79K shares |
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 2.70%824.87K shares |
STATE STREET CORP | 2.69%822.08K shares |
Allianz Asset Management GmbH | 2.66%811.32K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.61%795.91K shares |
MACKENZIE FINANCIAL CORP | 2.60%793.51K shares |
DIMENSIONAL FUND ADVISORS LP | 2.59%791.09K shares |
Jefferies Financial Group Inc. | 2.12%647.39K shares |
Qube Research & Technologies Ltd | 1.93%589.3K shares |
AIGH Capital Management LLC | 1.79%545.1K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.22%371.2K shares |
GOLDMAN SACHS GROUP INC | 1.17%358.4K shares |
Point72 Asset Management, L.P. | 1.17%357.32K shares |
KENNEDY CAPITAL MANAGEMENT LLC | 1.14%348.37K shares |
Connor, Clark & Lunn Investment Management Ltd. | 1.09%331.73K shares |
Percentages use 30.51M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 · 10b5-1 | Oelschlager Kristen MChief Operating Officer | SellCommon Stock | 8.6K | $20.71 | $177.8K | 30.5K |
| Jun 15, 2026Form 4 · 10b5-1 | MAETZOLD DEREK JPres. & Chief Exec. Officer | SellCommon Stock · indirect | 278 | $20.66 | $5.7K | 12.6K |
| Jun 15, 2026Form 4 · 10b5-1 | MAETZOLD DEREK JPres. & Chief Exec. Officer | SellCommon Stock · indirect | 278 | $20.66 | $5.7K | 12.6K |
| Jun 15, 2026Form 4 · 10b5-1 | MAETZOLD DEREK JPres. & Chief Exec. Officer | SellCommon Stock · indirect | 278 | $20.66 | $5.7K | 12.6K |
| Jun 15, 2026Form 4 · 10b5-1 | MAETZOLD DEREK JPres. & Chief Exec. Officer | SellCommon Stock · indirect | 278 | $20.66 | $5.7K | 12.6K |